Create Free Account

By creating account you will get access to hot stocks & personalised emails

Medical Developments International

Healthcare AU MVP

0.45AUD
-0.01(2.17%)

Last update at 2024-05-02T06:10:00Z

Day Range

0.420.46
LowHigh

52 Week Range

0.421.80
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -7.49200M -15.90800M -14.97800M 0.32M 1.55M
Minority interest - - - - -
Net income -5.60900M -12.40700M -12.56500M 0.38M 1.04M
Selling general administrative 32.58M 22.21M 15.23M 5.59M 5.40M
Selling and marketing expenses 3.83M 2.60M 4.75M 5.38M 4.27M
Gross profit 22.04M 15.63M 19.10M 14.99M 14.18M
Reconciled depreciation 3.11M 2.94M 3.75M 2.60M 2.27M
Ebit -0.68800M -15.22400M -6.01300M 0.43M 1.62M
Ebitda 2.42M -10.68500M -2.26400M 3.03M 3.89M
Depreciation and amortization 3.11M 4.54M 3.75M 2.60M 2.27M
Non operating income net other - - - - -
Operating income -17.30400M -12.54500M -3.47400M 2.44M 1.62M
Other operating expenses -20.14100M -24.74900M -30.66800M -7.34500M 21.97M
Interest expense 0.10M 0.10M 0.00900M 0.11M 0.07M
Tax provision -1.88300M -3.50100M -2.41300M -0.05800M 0.51M
Interest income 0.66M 0.04M 0.07M 0.34M 0.45M
Net interest income 0.56M -0.05800M -0.05000M -0.11400M 0.38M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.88300M -3.50100M -2.41300M -0.05800M 0.51M
Total revenue 32.17M 22.37M 25.27M 22.54M 20.88M
Total operating expenses 42.48M 32.50M 28.82M 17.49M 15.28M
Cost of revenue 10.12M 6.74M 6.17M 7.54M 6.69M
Total other income expense net 12.39M -0.58100M -8.95600M -2.12000M -0.07100M
Discontinued operations - - - - -
Net income from continuing ops -5.60900M -12.40700M -12.56500M 0.38M 1.04M
Net income applicable to common shares -5.60900M -12.40700M -12.56500M 0.38M 1.04M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 101.31M 92.22M 100.17M 84.76M 84.80M
Intangible assets 34.51M 36.88M 34.46M 35.82M 29.67M
Earning assets - - - - -
Other current assets 0.79M 0.78M 2.73M 0.45M 0.30M
Total liab 20.00M 34.92M 31.87M 41.42M 40.21M
Total stockholder equity 81.31M 57.30M 68.30M 43.34M 44.59M
Deferred long term liab 32.70M 35.12M 32.81M 33.87M 27.72M
Other current liab 1.59M 4.88M 3.25M 1.56M 3.75M
Common stock 105.73M 76.99M 76.89M 40.95M 40.41M
Capital stock 105.73M 76.99M 76.89M 40.95M 40.41M
Retained earnings -30.15400M -24.54500M -12.13800M 0.43M 2.67M
Other liab 2.24M 21.98M 22.20M 30.27M 31.73M
Good will 3.81M 3.81M 4.39M 9.10M 9.10M
Other assets 8.11M 40.74M 35.05M 35.98M 29.85M
Cash 24.66M 20.40M 36.28M 15.54M 25.62M
Cash and equivalents 24.66M 20.40M 36.28M 15.54M 25.62M
Total current liabilities 15.55M 10.48M 6.96M 8.21M 8.39M
Current deferred revenue 0.28M 0.08M 0.07M 2.39M 2.52M
Net debt -22.10100M -17.58500M -33.22800M -12.18800M -25.43800M
Short term debt 0.35M 0.35M 0.34M 0.42M 0.09M
Short long term debt - - - 0.09M 0.09M
Short long term debt total 2.56M 2.81M 3.05M 3.36M 0.18M
Other stockholder equity -75.57500M -52.44700M -64.75700M -41.38100M 1.51M
Property plant equipment 12.12M 11.55M 11.70M 11.78M 8.56M
Total current assets 42.76M 34.37M 47.39M 25.96M 35.35M
Long term investments - - - - -
Net tangible assets 75.70M 51.74M 62.27M 32.29M 33.55M
Short term investments - - - - -
Net receivables 8.93M 6.08M 2.65M 4.08M 6.38M
Long term debt - - 0.00000M 0.00000M 0.09M
Inventory 8.38M 7.11M 5.73M 5.88M 3.05M
Accounts payable 13.32M 5.17M 3.30M 3.84M 2.03M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 5.74M 4.85M 3.54M 1.96M 1.51M
Additional paid in capital - - - - -
Common stock total equity - - - 40.95M 40.41M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -17.73800M -17.11400M 0.00100M -22.73900M -0.00100M
Deferred long term asset charges - - - - -
Non current assets total 58.55M 57.85M 52.79M 58.80M 49.45M
Capital lease obligations 2.56M 2.81M 3.05M 3.27M -
Long term debt total 2.21M 2.46M 2.71M 2.94M 0.09M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -7.09900M -5.15900M -6.47800M -8.47200M -9.53500M
Change to liabilities 2.36M 0.90M 1.02M 1.97M 0.20M
Total cashflows from investing activities -7.09900M -5.15900M -6.47800M -8.47200M -9.53500M
Net borrowings -0.25300M -0.21500M -0.23200M -0.28800M -9.07000M
Total cash from financing activities 28.06M 0.14M 36.12M -1.96600M 13.04M
Change to operating activities -0.15400M -0.01900M -10.22300M -1.65600M 18.65M
Net income -5.60900M -12.40700M -12.56500M 0.38M 1.04M
Change in cash 4.26M -15.87900M 20.73M -10.07600M 24.83M
Begin period cash flow 20.40M 36.28M 15.54M 25.62M 0.79M
End period cash flow 24.66M 20.40M 36.28M 15.54M 25.62M
Total cash from operating activities -16.49500M -10.72200M -8.80800M 0.17M 21.27M
Issuance of capital stock 30.00M 0.36M 37.07M 0.40M 24.88M
Depreciation 3.11M 2.94M 3.75M 1.53M 2.27M
Other cashflows from investing activities 0.57M 0.06M 0.08M 0.43M 0.33M
Dividends paid 26.38M 0.14M 35.53M 2.06M 1.72M
Change to inventory -1.84200M -1.37400M 0.15M -2.83300M 0.15M
Change to account receivables -2.87000M -2.50000M 1.43M 2.30M -2.09700M
Sale purchase of stock -1.68400M -0.00300M -0.72700M -0.01300M -1.04500M
Other cashflows from financing activities 28.06M 0.14M 36.12M -0.19700M -0.01100M
Change to netincome -12.06100M 1.68M 7.54M -2.59100M 1.06M
Capital expenditures 7.67M 5.21M 6.56M 8.90M 9.87M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -2.50400M -3.59000M -9.92000M -0.53100M 20.90M
Stock based compensation 1.26M 1.03M 1.17M 0.09M -
Other non cash items -5.38100M 9.75M 8.89M -1.73500M -3.30400M
Free cash flow -24.16000M -15.93600M -15.36800M -8.72900M 11.41M

Fundamentals

  • Previous Close 0.46
  • Market Cap39.70M
  • Volume401923
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-20.82700M
  • Revenue TTM33.55M
  • Revenue Per Share TTM0.39
  • Gross Profit TTM 22.21M
  • Diluted EPS TTM-0.23

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MVP
Medical Developments International		 -0.01 2.17% 0.45 - 178.57 1.50 0.67 1.12 -1.8019
AFP
AFT Pharmaceuticals Ltd		 -0.02 0.72% 2.77 31.00 17.06 1.79 4.41 2.18 16.66
PBP
Probiotec Ltd		 -0.03 1.05% 2.83 28.30 - 1.06 2.64 1.39 8.58
VLS
Vita Life Sciences Ltd		 -0.02 0.87% 2.27 13.35 - 1.73 2.97 1.41 7.98
NXS
Next Science Ltd		 -0.005 1.54% 0.32 - 128.21 4.47 5.03 3.90 -5.9908

Reports Covered

Stock Research & News

View All

Profile

Medical Developments International Limited manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally. The company operates through Pain Management and Respiratory segments. It offers respiratory devices for sufferers of asthma and chronic obstructive pulmonary disease (COPD); and Penthrox, a trauma and emergency pain relief product; and medical devices. The company also provides asthma and COPD products, such as space chambers and silicone face masks. The company was founded in 1971 and is headquartered in Scoresby, Australia.

Medical Developments International

4 Caribbean Drive, Scoresby, VIC, Australia, 3179

Key Executives

Name Title Year Born
Mr. Brent MacGregor Chief Exec. Officer 1964
Ms. Anita James Chief Financial Officer NA
Matthew Cramer Chief of Operations & Supply Chain NA
Ms. Tara Eaton Gen. Counsel & Company Sec. NA
Ms. Greer Lucas Head of People & Culture NA
Dr. Scott Courtney Chief Scientific Officer NA
Wai Ng Chi Head of Regulatory Affairs NA
Wayne Pearce Head of Production NA
Mr. Stefaan Schatteman Head of Europe NA
Mr. Brent MacGregor Chief Executive Officer 1964

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Our Company

Useful Links

Contact Us

Market Research

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.